Figure S1. Protein expression levels of GAPDH protein in OVCA tissue samples. (A) Western blotting was performed to detect GAPDH expression in 3 pairs of OVCA tissues (T) and their matching adjacent normal tissues (N). β-actin was used as the internal control. (B) Quantification of western blots. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; OVCA, ovarian cancer.



Figure S2. The expression of GAPDH and miR-125b in OVCA mutant tissues and OVCA wild-type tissues. (A) The abundance of GAPDH mutation (NM_001289745.2:c.*1325_*1326insC) in 11 OVCA mutant tissues. (B) mRNA expression levels of GAPDH in OVCA mutant (MUT) tissues, compared with OVCA wild-type (WT) tissues, n=11. (C) mRNA expression levels of miR-125b in OVCA MUT tissues, compared with OVCA WT tissues, n=11. OVCA, ovarian cancer; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; T-GAPDH-WT, tumor tissues with wild-type GAPDH; T-GAPDH-MUT, tumor tissues with mutant GAPDH.

A

Abundance of GAPDH mutation in 11 OVCA samples (NM_001289745.2:c.*1325_*1326insC)	
1	0.41%
2	10.67%
3	3.26%
4	0.72%
5	1.43%
6	7.92%
7	10.05%
8	8.34%
9	1.32%
10	7.48%
11	9.44%